SAB Biotherapeutics (SABS) Stock Forecast, Price Target & Predictions
SABS Stock Forecast
SAB Biotherapeutics stock forecast is as follows: an average price target of $5.67 (represents a 103.23% upside from SABS’s last price of $2.79) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
SABS Price Target
The average price target for SAB Biotherapeutics (SABS) is $5.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $3.00. This represents a potential 103.23% upside from SABS's last price of $2.79.
SABS Analyst Ratings
According to 4 Wall Street analysts, SAB Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SABS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
SAB Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | 181.69% | 186.74% |
| Apr 02, 2024 | Edward White | H.C. Wainwright | $6.00 | $4.29 | 39.86% | 115.05% |
| Aug 11, 2022 | - | Chardan Capital | $3.00 | $1.12 | 167.86% | 7.53% |
The latest SAB Biotherapeutics stock forecast, released on Jun 07, 2024 by Kumaraguru Raja from Loop Capital Markets, set a price target of $8.00, which represents a 181.69% increase from the stock price at the time of the forecast ($2.84), and a 186.74% increase from SABS last price ($2.79).
SAB Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.79 | $2.79 | $2.79 |
| Upside/Downside | -100.00% | -100.00% | 150.90% |
In the current month, the average price target of SAB Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SAB Biotherapeutics's last price of $2.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jun 07, 2024 | Brookline Capital | - | Buy | Initialise |
| Apr 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 11, 2022 | Chardan Capital | Buy | Buy | Hold |
| May 13, 2022 | Chardan Capital | Buy | Buy | Hold |
SAB Biotherapeutics's last stock rating was published by Oppenheimer on Aug 27, 2024. The company Initialise its SABS rating from "null" to "Outperform".
SAB Biotherapeutics Financial Forecast
SAB Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.27M | $85.52K | $581.10K | $2.16M | $3.59M | - | $11.80M | $60.88M | - |
| Avg Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $125.00K | $263.14K | $944.58K | $305.01K | $11.97K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $14.40M |
| High Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $125.00K | $263.14K | $944.58K | $305.01K | $11.97K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $17.28M |
| Low Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $125.00K | $263.14K | $944.58K | $305.01K | $11.97K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $11.52M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | - | - | - | 8 | 6 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 105.91% | 0.21% | 0.23% | 0.37% | 0.52% | - | 1.03% | 3.60% | - |
SAB Biotherapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $305.01K, with a low forecast of $305.01K, and a high forecast of $305.01K. SABS's average Quarter revenue forecast represents a -75.93% decrease compared to the company's last Quarter revenue of $1.27M (Sep 23).
SAB Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | - | - | - | 8 | 6 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-4.23M | $-6.48M | $-6.42M | $-7.80M | $-6.88M | - | $-6.02M | $-11.52M | $-337.35K |
| Avg Forecast | $-140.49K | $-140.49K | $-140.49K | $-140.49K | $-70.24K | $-70.24K | $-147.87K | $-530.80K | $-171.40K | $-6.72K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-539.75K |
| High Forecast | $-140.49K | $-140.49K | $-140.49K | $-140.49K | $-70.24K | $-70.24K | $-147.87K | $-530.80K | $-171.40K | $-6.72K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-431.80K |
| Low Forecast | $-140.49K | $-140.49K | $-140.49K | $-140.49K | $-70.24K | $-70.24K | $-147.87K | $-530.80K | $-171.40K | $-6.72K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-647.70K |
| Surprise % | - | - | - | - | - | - | - | - | - | 628.48% | 28.81% | 4.50% | 2.35% | 1.79% | - | 0.93% | 1.21% | 0.63% |
undefined analysts predict SABS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than SAB Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
SAB Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | - | - | - | 8 | 6 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $-5.10M | $-6.88M | $-7.40M | $-7.87M | $-6.34M | - | $985.86K | $-17.88M | $-326.11K |
| Avg Forecast | $-6.11M | $-6.20M | $-6.39M | $-8.93M | $-10.55M | $-10.16M | $-10.61M | $-8.87M | $-3.67M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.01M | $-8.50M | $-5.14M | $-529.33K |
| High Forecast | $-6.11M | $-6.20M | $-6.39M | $-8.93M | $-10.55M | $-10.06M | $-10.61M | $-8.87M | $-3.67M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.01M | $-8.50M | $-5.14M | $-423.46K |
| Low Forecast | $-6.11M | $-6.20M | $-6.39M | $-8.93M | $-10.55M | $-10.35M | $-10.61M | $-8.87M | $-3.67M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.01M | $-8.50M | $-5.14M | $-635.19K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.47% | 0.53% | 0.71% | 0.87% | 0.48% | - | -0.12% | 3.48% | 0.62% |
SAB Biotherapeutics's average Quarter net income forecast for Jul 22 is $-12.01M, with a range of $-12.01M to $-12.01M. SABS's average Quarter net income forecast represents a -1318.68% decrease compared to the company's last Quarter net income of $985.86K (Mar 22).
SAB Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | - | - | - | 8 | 6 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $2.57M | $2.90M | $3.45M | $2.88M | $4.04M | - | $5.19M | $17.09M | - |
| Avg Forecast | $561.77K | $561.77K | $561.77K | $561.77K | $280.88K | $280.88K | $591.29K | $2.12M | $685.38K | $26.89K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $32.36M |
| High Forecast | $561.77K | $561.77K | $561.77K | $561.77K | $280.88K | $280.88K | $591.29K | $2.12M | $685.38K | $26.89K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $38.83M |
| Low Forecast | $561.77K | $561.77K | $561.77K | $561.77K | $280.88K | $280.88K | $591.29K | $2.12M | $685.38K | $26.89K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $25.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | 95.60% | 3.23% | 0.60% | 0.22% | 0.26% | - | 0.20% | 0.45% | - |
SAB Biotherapeutics's average Quarter SG&A projection for Dec 23 is $685.38K, based on 2 Wall Street analysts, with a range of $685.38K to $685.38K. The forecast indicates a -73.34% fall compared to SABS last annual SG&A of $2.57M (Sep 23).
SAB Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | - | - | - | 8 | 6 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.14 | $-0.15 | $-0.18 | $-0.15 | - | $0.02 | $-0.41 | $-0.09 |
| Avg Forecast | $-0.66 | $-0.67 | $-0.69 | $-0.96 | $-1.14 | $-1.10 | $-1.15 | $-0.96 | $-0.62 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
| High Forecast | $-0.66 | $-0.67 | $-0.69 | $-0.96 | $-1.14 | $-1.09 | $-1.15 | $-0.96 | $-0.62 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
| Low Forecast | $-0.66 | $-0.67 | $-0.69 | $-0.96 | $-1.14 | $-1.12 | $-1.15 | $-0.96 | $-0.62 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.08% | 0.10% | 0.13% | 0.18% | 0.10% | - | -0.01% | 0.47% | -0.08% |
According to 0 Wall Street analysts, SAB Biotherapeutics's projected average Quarter EPS for Jul 22 is $-1.30, with a low estimate of $-1.30 and a high estimate of $-1.30. This represents a -6600.00% decrease compared to SABS previous annual EPS of $0.02 (Mar 22).
SAB Biotherapeutics Peer Comparison by Price Target
SABS Forecast FAQ
Is SAB Biotherapeutics a good buy?
Yes, according to 4 Wall Street analysts, SAB Biotherapeutics (SABS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of SABS's total ratings.
What is SABS's price target?
SAB Biotherapeutics (SABS) average price target is $5.67 with a range of $3 to $8, implying a 103.23% from its last price of $2.79. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will SAB Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for SABS stock, the company can go up by 103.23% (from the last price of $2.79 to the average price target of $5.67), up by 186.74% based on the highest stock price target, and up by 7.53% based on the lowest stock price target.
Can SAB Biotherapeutics stock reach $4?
SABS's average twelve months analyst stock price target of $5.67 supports the claim that SAB Biotherapeutics can reach $4 in the near future.
What are SAB Biotherapeutics's analysts' financial forecasts?
SAB Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.46M (high $1.46M, low $1.46M), average EBITDA is $-819K (high $-819K, low $-819K), average net income is $-40.193M (high $-40.098M, low $-40.383M), average SG&A $3.28M (high $3.28M, low $3.28M), and average EPS is $-4.344 (high $-4.334, low $-4.365). SABS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-562K (high $-562K, low $-562K), average net income is $-27.626M (high $-27.626M, low $-27.626M), average SG&A $2.25M (high $2.25M, low $2.25M), and average EPS is $-2.985 (high $-2.985, low $-2.985).
Did the SABS's actual financial results beat the analysts' financial forecasts?
Based on SAB Biotherapeutics's last annual report (Dec 2023), the company's revenue was $2.24M, which missed the average analysts forecast of $3.26M by -31.26%. Apple's EBITDA was $-38.075M, beating the average prediction of $-1.83M by 1980.32%. The company's net income was $-42.194M, beating the average estimation of $-37.918M by 11.28%. Apple's SG&A was $23.8M, beating the average forecast of $7.32M by 225.19%. Lastly, the company's EPS was $-7.64, beating the average prediction of $-4.32 by 76.85%. In terms of the last quarterly report (Sep 2023), SAB Biotherapeutics's revenue was $1.27M, beating the average analysts' forecast of $11.97K by 10491.35%. The company's EBITDA was $-4.226M, beating the average prediction of $-6.724K by 62748.44%. SAB Biotherapeutics's net income was $-5.102M, missing the average estimation of $-10.798M by -52.75%. The company's SG&A was $2.57M, beating the average forecast of $26.89K by 9460.27%. Lastly, the company's EPS was $-0.0974, missing the average prediction of $-1.167 by -91.65%